Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

已完结 10 由 Aixuexi 发布于 2026/9/1 9:50:50

DOI:10.1016/S1470-2045(26)00282-2
作者：Xiuning Le,?Antonio Passaro,?Yuanyuan Zhao,?Yan Huang,?Janessa Laskin,?Delvys Rodriguez-Abreu,?Antonio Calles,?Lyudmila Bazhenova,?Giuseppe Lo Russo,?Natasha B Leighl,?Federico Cappuzzo,?Nicolas Girar
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Background: Ivonescimab has shown clinical efficacy in non-small-cell lung cancer (NSCLC). We aimed to assess the efficacy and safety of ivonescimab plus chemotherapy versus placebo plus che

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Efficient Atlas Generation for Medical Imaging Via Groupwise Latent Diffusion Models